Shopping Cart
- Remove All
Your shopping cart is currently empty
PF-06260933
Catalog No. T4221Cas No. 1811510-56-1
Alias PF-6260933, PF6260933, PF 6260933
PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
PF-06260933
Catalog No. T4221Alias PF-6260933, PF6260933, PF 6260933Cas No. 1811510-56-1
PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $42 | In Stock | |
| 2 mg | $58 | In Stock | |
| 5 mg | $105 | In Stock | |
| 10 mg | $166 | In Stock | |
| 25 mg | $342 | In Stock | |
| 50 mg | $547 | In Stock | |
| 100 mg | $789 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $105 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "PF-06260933"
sodium lauroyl-α-hydroxyethyl sulfonate
T7283
Sodium houttuyfonate is anti-pseudomonas agents, inhibits virulence-related motility of Pseudomonas.
- $53
Size
QTY
Vemurafenib
Cited
RO5185426, RG7204, PLX4032
T2382918504-65-1
Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma.
- $50
Size
QTY
CitedSKLB-163
SKLB163
T261931255099-06-9In house
SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK.
- $137
Size
QTY
CMPD1
T1498841179-33-3
CMPD1 is a non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor(apparent Ki (Kiapp): 330 nM).
- $31
Size
QTY
Takinib Cited
EDHS-206
T42641111556-37-6
Takinib (EDHS-206) is a specific and effective TAK1 inhibitor(IC50= 9.5 nM).
- $66
Size
QTY
CitedSodium lauryl sulfoacetate
Sodium houttuyfonate
T36031847-58-1
Sodium lauryl sulfoacetate (Sodium houttuyfonate) is anti-pseudomonas agents, inhibits virulence-related motility of Pseudomonas.
- $30
Size
QTY
Selonsertib Cited
GS-4997
T33501448428-04-3
Selonsertib (GS-4997) is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.
- $33
Size
QTY
CitedMBM-55S
T119612083624-07-9In house
MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer cells. MBM-55S shows antitumor activities.
- $195
Size
QTY
Nomilin
T36721063-77-0
Nomilin is naturally occurring triterpenoids, have immunomodulatory activity.
- $39
Size
QTY
MK2-IN-3 hydrate
MK-2 Inhibitor III
T120581186648-22-5
MK2-IN-3 hydrate (MK-2 Inhibitor III) is an orally active, selective, and ATP-competitive inhibitor of MAPKAP-K2 (MK-2) (IC50 of 0.85 nM)
- $48
Size
QTY
NQDI-1 Cited
NQDI1, NQDI 1
T3101175026-96-7
NQDI-1 (NQDI 1) is a selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1, MAP3K5) (IC50/Ki: 3 μM/500 nM).
- $40
Size
QTY
CitedSelect Batch
Purity:99.97%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively. |
| Targets&IC50 | MAP4K4:3.7 nM |
| In vitro | Treatment with PF-06260933 significantly enhances the resistance of human aortic endothelial cells (EC) to TNF-α-induced increases in endothelial permeability in vitro. |
| In vivo | Treatment with PF-06260933 does not modify plasma lipid content in a mouse model, yet it leads to decreased glucose levels, mirroring outcomes seen in whole-body-inducible Map4k4 knockout animals. Moreover, PF-06260933 administration results in either the attenuation of plaque progression or promotion of plaque regression in this model (46.0% versus 25.5%), alongside reductions in both plasma glucose and lipid content. |
| Alias | PF-6260933, PF6260933, PF 6260933 |
| Molecular Weight | 296.75 |
| Formula | C16H13ClN4 |
| Cas No. | 1811510-56-1 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (168.49 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy PF-06260933 | purchase PF-06260933 | PF-06260933 cost | order PF-06260933 | PF-06260933 chemical structure | PF-06260933 in vivo | PF-06260933 in vitro | PF-06260933 formula | PF-06260933 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.